Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this study enrolled 34,960 participants, all of whom had been diagnosed with a type of scarring lung disease (interstitial lung disease, or ILD) other than the most common form known as IPF. The study was observational, meaning researchers looked back at existing medical records rather than testing a new treatment. The main goal was to track how likely these patients were to have their lung disease worsen — described as "progression to pulmonary fibrosing ILD" — over a period of up to two years after their diagnosis. The reported data shows that the estimated likelihood of disease progression increased over time. By 6 months after diagnosis, approximately 14.7% of patients had shown signs of progression; by 12 months that figure rose to around 24.9%; by 18 months it was approximately 33.4%; and by 24 months it reached around 39.5%. These percentages are statistical estimates (meaning they are calculated approximations of risk across the whole group, not exact counts). The study also tracked what treatments and disease management approaches patients received during the follow-up period. Among the secondary findings, the reported data shows that oral corticosteroids were the most commonly recorded treatment, used by 2,065 participants, while nintedanib (a specific lung medication) was recorded for 472 participants. For disease management, oxygen therapy was recorded for 1,641 participants, palliative care measures for 9,520 participants, and no lung transplants were recorded in this group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Interstitial Lung Disease Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have been diagnosed with a scarring lung disease (called fibrosing Interstitial Lung Disease, or ILD) on at least two separate occasions recorded on different dates
- You are 18 years old or older at the time your records are reviewed for the study
- Your medical records from the 12 months before the study start date are available and can be used for background information
Who may not be able to join:
- You have been diagnosed specifically with Idiopathic Pulmonary Fibrosis (IPF), which is a particular type of scarring lung disease (confirm with trial site)
- Your scarring lung disease showed signs of getting worse during the 12-month period before the study start date (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.